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iDITORIAL COMMENT
yclooxygenase Inhibition
n Patients With
oronary Artery Disease*
illiam H. Frishman, MD, FACC
alhalla, New York
he prostanoids are receptor-activating lipid mediators that
xert a pervasive influence on body functioning because they
nvolve all organ systems and their effects can be heightened
y various disease states and pathophysiologic conditions
1). The enzyme cyclooxygenase (COX) catalyzes the intra-
ellular rate-limiting step in the formation of various pro-
tanoids from arachidonic acid. These prostanoids include
he prostaglandins PGD2, PGE2, PGF2, PGF2, and PGI2
prostacyclin) and the procoagulant thromboxane (TXA2),
ound in blood platelets (2). The multiplicity of prostaglan-
in and TXA2 receptors and their signaling systems has
ielded a combined molecular biologic, biochemical, and
harmacologic-physiologic approach that has defined their
tructures, distribution, properties, and function (1).
See page 526
There are also two known isoforms of the COX enzyme,
OX-1 and COX-2. Cyclooxygenase-1 is expressed in
ost body tissues and is the only COX isoform present in
lood platelets. In platelets, it converts arachidonic acid into
XA2 and is the main isoform found in the gastric mucosa,
here it catalyzes the cytoprotective prostaglandins (1,2).
nlike COX-1, COX-2 appears to be less involved in
ormal physiologic activity but is expressed more promi-
ently with active inflammation and other pathophysiologic
rocesses (2,3). It was this latter observation that led to the
linical development of selective COX-2 inhibitors that
ould provide clinical anti-inflammatory activity while
paring the cytoprotective prostaglandins produced by the
astric mucosa (4).
In addition to the prostanoids produced by COX activity,
here are analogs of prostaglandins known as isoprostanes
hat can be formed by oxygen-derived free radical attack on
rachidonic acid as well as by COX (5,6). Some of these
soprostanes, such as 8-epi-PGF2, have biologic activities
imilar to TXA2 (7). In human atherosclerosis, there is a
arked elevation in both TXA2 and epi-PGF2, which may
e contributing to the increased risk of thrombosis and
estenosis in patients undergoing coronary angioplasty. The
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Medicine, Division of Cardiology, New York MedicalTollege/Westchester Medical Center, Valhalla, New York.ormation of epi-PGF2 with increased thromboxane activ-
ty may be induced by COX-2, which could bypass TXA2
ormed by COX-1. Therefore, a drug such as aspirin, which
nhibits platelet TXA2, might not be effective as an antico-
gulant in all patients.
Aspirin has been shown to be beneficial in reducing the
isk of myocardial infarction and stroke in patients with
therosclerosis (8). The critical action of aspirin on platelets
s the inhibition of PGH2 production by COX-1 because
GH2 is the obligatory precursor of TXA2, the final
roduct of platelet metabolism of arachidonic acid via
OX-1 and TXA2 synthetase activity (8).
In patients with unstable angina, another factor, one that
s not attributable to platelets, appears to be operative and
esponsible for TXA2 production by both COX-1 and
OX-2 that is associated with atherosclerotic plaques (9).
n a significant number of patients, thromboxane produc-
ion is only partially inhibited by aspirin, as reflected by the
rinary excretion of thromboxane metabolites despite com-
lete suppression of TXA2 formation by aspirin in platelets
10). Atherosclerotic plaques and contiguous tissue of the
iseased arteries are the presumed source of aspirin-
nsensitive TXA2. Aspirin also inhibits prostacyclin forma-
ion from endothelial cells (8). Prostacyclin has vascular
rotective action (vasodilator, inhibitor of platelet aggrega-
ion, and mesenchymal proliferation); however, the con-
omitant suppression of TXA2 predominates, and the func-
ional consequence is cardioprotection (8).
Traditional nonsteroidal anti-inflammatory drugs also
nhibit COX-1-derived TXA2 and COX-derived prostacy-
lin. However, the effect is reversible during the dosing
nterval, and this transient effect would not be expected to
rovide cardioprotection (2). There are also recent data to
uggest that the use of a nonsteroidal anti-inflammatory
rug might inhibit the benefits of aspirin (11).
The selective COX-2 inhibitors can inhibit prostacyclin
ormation in atherosclerotic blood vessels, while having no
ffects on COX-1-derived TXA2. The net effect would be a
otentiation of thrombotic activity (3). However, COX-2
nhibition might also inhibit the formation of prothrom-
otic isoprostanes, such as 8-epi-PGF2.
The study by Kearney et al. (12) in this issue of the
ournal sought out to test the hypothesis that the addition of
he COX-2 inhibitor nimesulide would provide an addi-
ional antiplatelet effect over that of concomitant aspirin use
n patients undergoing coronary angioplasty. However, the
esults of the study showed no additional effect of adding
imesulide to aspirin on TXA2 levels and no effect of the
spirin-nimesulide combination on the levels of the isopros-
ane 8-epi-PGF2 (12). The addition of nimesulide to
spirin did cause a reduction in prostacyclin production
12).
This important study confirms past observations regard-
ng the effects of aspirin and selective COX-2 inhibitors on
XA2 and prostacyclin production while showing that the
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hrough COX activity (1,8). Optimal suppression of TXA2
s achieved by the use of aspirin alone; however, in patients
ith atherosclerosis, not all thromboxane-like activity is
nhibited by aspirin (e.g., 8-epi-PGF2) (12).
In addition to aspirin, pharmacologic approaches that
ave been used to achieve greater suppression of TXA2
ctions have included agents that directly block the TXA2/
GH2 receptor, agents that interfere with thromboxane
ynthetase, and agents that provide combined thromboxane
ynthesis inhibition and TXA2/PGH2 receptor blockade
8). These agents would also preserve prostacyclin synthesis;
owever, the clinical studies to date show no benefit beyond
hat is observed with aspirin (8). A potential strategy would
e a pharmacologic intervention that would interfere with
he production and/or activity of 8-epi-PGF2 to be used
ith aspirin for maximizing antiplatelet activity.
As shown by Kearney et al. (12), selective COX-2
nhibitors do not effect TXA2 production and may decrease
he production of prostacyclin, suggesting potential harm
rom using these drugs in patients with atherosclerotic
ascular disease. However, most of the available data suggest
o clinical risk, and the results of a recent study suggest that
OX-2 inhibitors may, in fact, be protective in patients
ith coronary artery disease because of their potent anti-
nflammatory actions, which manifest as improved
ndothelium-dependent vasodilation with reductions in
-reactive protein levels and oxidized low-density lipopro-
ein plasma levels (13).
However, because of current concerns regarding the
ardiovascular safety of selective COX-2 inhibitors, current
uidelines suggest that arthritic patients with cardiovascular
isease risk factors should receive low-dose aspirin when
eing prescribed a selective COX-2 inhibitor (1). Once
XA2-mediated platelet aggregation is sufficiently blocked
y aspirin, the additional pleiotropic actions of COX-2
nhibitors related to their anti-inflammatory actions may
ome into play and could provide an overall beneficial effect
n cardiovascular outcomes. Much evidence is now accu-
ulating that unstable coronary artery disease may be an
ctive inflammatory process (14,15). Clinical trials need to
e conducted to test this intriguing new hypothesis that
nti-inflammatory drug treatment with COX-2 inhibition
an actually protect against unstable cardiovascular syn-
romes.eprint requests and correspondence: Dr. William H. Frish-
an, Department of Medicine, New York Medical College,
unger Pavilion 263, Valhalla, New York 10595. E-mail:
illiam_Frishman@nymc.edu.
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